Legend Biotech Corporation LEGN
20.41 USD -3.88 (-15.97%)
At closeNov 10, 2026, 7:13 PM EST
20.55 +0.14 +0.69%
After hours · Nov 10, 7:13 PM ET
19.76 Day range 22.85
16.24 52-week range 37.50
- YTD
- -6.12%
- 1 year
- -35.39%
News
seekingalpha.com Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript
marketbeat.com What Legend Biotech (LEGN) Said on Its Q3 Earnings Call Legend Biotech NASDAQ: LEGN reported 36% growth in third-quarter global net trade sales of its multiple myeloma treatment CARVYKTI, while executives said slower-than-anticipated gains in earlier-line…
benzinga.com Legend Biotech Q3 2026 Earnings Call Transcript Legend Biotech (NASDAQ:LEGN) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to…
benzinga.com Legend Biotech Q3 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $359.500M Miss $361.619M Estimate Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of $0.14 per share which beat the analyst consensus estimate of $0.00 by Infinity percent. This is a 380 percent increase over losses of…
globenewswire.com Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 36% versus third quarter of 2025 to approximately $710 million Half of CARTITUDE-2 Cohort A patients remained alive and…
benzinga.com Petrobras, TransDigm On Deck Tuesday As Oil Profits, Aerospace Demand Face Test Petroleo Brasileiro headlines Tuesday’s reports, with investors weighing whether strong production and operating performance can offset pressure on energy prices. TransDigm Group, Honda Motor, Sea,…
globenewswire.com Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026 New CARTITUDE-4 subgroup analyses provide further insights into durable clinical outcomes with CARVYKTI in earlier-line treatment Updated data to be presented from first-in-human trial of LB2501, an…
zacks.com Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average From a technical perspective, Legend Biotech Corporation Sponsored ADR (LEGN) is looking like an interesting pick, as it just reached a key level of support. LEGN recently overtook the 200-day moving…
zacks.com Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors After reaching an important support level, Legend Biotech Corporation Sponsored ADR (LEGN) could be a good stock pick from a technical perspective. LEGN surpassed resistance at the 50-day moving…
globenewswire.com Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results BRIDGEWATER N.J., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 a.m.
seekingalpha.com Legend Biotech: Carvykti Makes Billions, But The Profits Are Elusive CARVYKTI's quarterly sales reached $710 million, but Legend's high expenses have kept recurring profitability low. Q2 results show improving operating leverage, with collaboration revenue growing…
globenewswire.com Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy LB2501 is an off-the-shelf in vivo CAR-T therapy designed to generate dual-targeting CD19/CD20 CAR-T cells directly within the patient after a single infusion, making it the first known…
benzinga.com Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $68 Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $74 to $68.
benzinga.com JP Morgan Maintains Neutral on Legend Biotech, Lowers Price Target to $33 JP Morgan analyst Jessica Fye maintains Legend Biotech (NASDAQ:LEGN) with a Neutral and lowers the price target from $35 to $33.
benzinga.com RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $56 RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $58 to $56.
globenewswire.com Legend Biotech Launches Inaugural ELITE Grant Program to Advance the Next Generation of CAR-T Innovation in Multiple Myeloma Annual program will award funding to early-career healthcare professionals advancing research, education, and innovation in multiple myeloma BRIDGEWATER, N.J., Oct. 01, 2026 (GLOBE NEWSWIRE) --…- benzinga.com HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.
defenseworld.net Legend Biotech Corporation Sponsored ADR (NASDAQ:LEGN) Stock Has Consensus Price Target of $53.14 According to Analysts Legend Biotech Corporation Sponsored ADR (NASDAQ: LEGN - Get Free Report) has been assigned a consensus rating of "Hold" from the fifteen brokerages that are currently covering the company,…
benzinga.com Legend Biotech Reports 50% Of CARTITUDE-2 Patients Remained Progression-Free At 5 Years After Single CARVYKTI Infusion Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMMBRIDGEWATER, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) --…
globenewswire.com Legend Biotech Presents CARVYKTI Data Showing Half of Patients with RRMM Remained Progression-Free and Alive Five Years After a Single Infusion Five-year overall survival rate was 69.2%, adding to growing long-term evidence supporting the curative potential of CARVYKTI in earlier-line RRMM
reuters.com Legend Biotech taps Novartis veteran Zhang as CEO Legend Biotech on Tuesday appointed longtime Novartis executive Ingrid Zhang as its CEO, effective immediately, banking on an industry veteran to steer its expansion beyond blockbuster cancer…
globenewswire.com Legend Biotech Appoints Ingrid Zhang as Chief Executive Officer BRIDGEWATER, N.J., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that its Board of…
wsj.com Legend Biotech is tapping a Novartis executive to run the cell-therapy maker, ending a nearly two-month search that began when former CEO Ying Huang resigned in July Ingrid Zhang will take the helm of the cancer therapy company, filling a post vacant since its previous CEO abruptly resigned in July.- benzinga.com Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $74 Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $78 to $74.
- benzinga.com Legend Biotech To Present Data For Its CARTITUDE-2 Trial Of CARVYKTI At 23rd International Myeloma Society Annual Meeting Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that data from CARTITUDE-2 and real-world evidence will be presented at the 23rd…
globenewswire.com Legend Biotech to Present Updated Long-Term and Real-World Evidence from CARVYKTI Clinical Program at the International Myeloma Society Annual Meeting Updated long-term follow-up data will be presented from CARTITUDE-2 Cohort A in patients with lenalidomide-refractory multiple myeloma after 1-3 prior lines of therapy Real-world evidence and…- benzinga.com HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.
globenewswire.com Legend Biotech to Participate in the Morgan Stanley Global Healthcare Conference BRIDGEWATER N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Alan Bash, interim Chief…
benzinga.com This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.- benzinga.com Morgan Stanley Maintains Overweight on Legend Biotech, Raises Price Target to $49 Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and raises the price target from $48 to $49.
- benzinga.com TD Cowen Maintains Hold on Legend Biotech, Lowers Price Target to $24 TD Cowen analyst Yaron Werber maintains Legend Biotech (NASDAQ:LEGN) with a Hold and lowers the price target from $29 to $24.
- benzinga.com Oppenheimer Downgrades Legend Biotech to Perform, Lowers Price Target to $40 Oppenheimer analyst Trevor Allred downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to Perform and lowers the price target from $75 to $40.
benzinga.com RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $58 RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $59 to $58.- benzinga.com Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $78 Barclays analyst Etzer Darout maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $80 to $78.
247wallst.com Here Are Wednesday’s Top Wall Street Analyst Research Calls: The Gap, Genmab, Hilton Worldwide, Intuitive Surgical, Marriott International, Merck, Novo Nordisk, Okta, and More With all eyes locked on this morning's CPI release and the Strait of Hormuz nearly shut down, Wall Street analysts are already repositioning across hospitality, pharma, and tech before the market…
seekingalpha.com Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript Legend Biotech Corporation (LEGN) Q2 2026 Earnings Call Transcript
247wallst.com Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus Shares of Legend Biotech (NASDAQ:LEGN | LEGN Price Prediction) are climbing 6% to $21.88 Tuesday midday after the company reported Q2 2026 results that paired a solid revenue beat with the first…
benzinga.com Legend Biotech Q2 Adj. EPS $0.16 Beats $0.07 Estimate, Sales $387.500M Beat $355.772M Estimate Legend Biotech (NASDAQ:LEGN) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.07 by 100 percent. This is a 147.06 percent increase over losses of $(0.34)…
benzinga.com Top 3 Health Care Stocks You'll Regret Missing This Quarter The most oversold health care stocks present a buying opportunity. RSI indicator compares stock strength on up and down days, indicating short-term performance. Here's the latest list of oversold…
benzinga.com HC Wainwright & Co. Reiterates Buy on Legend Biotech, Maintains $65 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Legend Biotech (NASDAQ:LEGN) with a Buy and maintains $65 price target.
benzinga.com RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $59 RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $63 to $59.- benzinga.com Legend Biotech CEO Ying Huang Steps Down, Alan Bash Named Interim CEO Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that Ying Huang, Ph.D., has stepped down as Chief Executive Officer and…
- benzinga.com UBS Downgrades Legend Biotech to Neutral, Lowers Price Target to $28 UBS analyst Ashwani Verma downgrades Legend Biotech (NASDAQ:LEGN) from Buy to Neutral and lowers the price target from $49 to $28.
benzinga.com Top 3 Health Care Stocks That May Rocket Higher In July Health care sector oversold - buying opportunities in undervalued companies. RSI compares stock strength on up/down days, below 30 is oversold.- benzinga.com JP Morgan Reinstates Neutral on Legend Biotech, Announces $35 Price Target JP Morgan analyst Jessica Fye reinstates Legend Biotech (NASDAQ:LEGN) with a Neutral and announces $35 price target.
- benzinga.com RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $63 RBC Capital analyst Leonid Timashev maintains Legend Biotech (NASDAQ:LEGN) with a Outperform and lowers the price target from $64 to $63.
benzinga.com Why Is Legend Biotech Stock Falling Thursday? Legend Biotech (LEGN) shares drop in premarket trading after pricing a $226M public offering. Get the latest technical levels here.
benzinga.com Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Session US stock futures up, Nasdaq futures 1% higher. Legend Biotech (LEGN) priced 7.7 million ADSs at $29.35 each, shares down 9% in pre-market trading.
benzinga.com Why Smith & Wesson Brands Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket Smith & Wesson (SWBI) shares rose in pre-market trading after posting strong Q4 results, beating earnings and revenue estimates. Other gainers include LNKS, ADTX, and SPRO.- benzinga.com Legend Biotech Commences $225M Offering Of Its American Depositary Shares Legend Biotech Corporation (NASDAQ:LEGN) ("Legend Biotech" or the "Company"), a global leader in cell therapy, today announced that it has commenced an underwritten public offering of $225 million of…